Effect of magnesium sulfate on bronchoconstriction in the lung periphery

Karen Sue Lindeman, C. A. Hirshman, A. N. Freed

Research output: Contribution to journalArticle

Abstract

Magnesium sulfate has been shown to be effective clinically as a bronchodilator, but its mechanism of action is unknown. We used a wedged bronchoscope technique to study the ability of MgSO4 at clinically relevant concentrations to attenuate hypocapnia-, acetylcholine- (ACh), and dry air-induced bronchoconstriction in the canine lung periphery. Control experiments demonstrated that consecutive challenges of either hypocapnia or ACh resulted in greater collateral system resistance (Rcs) after the second challenge compared with the first. Intravenous infusion of MgSO4 diminished the maximum response to a second hypocapnic challenge (Rcs = 1.59 ± 0.29 cmH2O·ml-1·s prechallenge vs. 1.12 ± 0.20 postchallenge) but had no effect on either ACh- or dry air-induced bronchoconstriction. Serum magnesium levels before MgSO4 administration were 1.59 ± 0.04 meq/l and rose to 6.20 ± 0.13 during the infusion. Previous studies demonstrated that nifedipine, like MgSO4 in this study, attenuates hypocapnia-induced bronchoconstriction in the canine lung periphery but has no effect on ACh- or dry air-induced bronchoconstriction. We conclude that these results are consistent with the idea that, like nifedipine, magnesium acts in the airway as a voltage-sensitive calcium channel blocker.

Original languageEnglish (US)
Pages (from-to)2527-2532
Number of pages6
JournalJournal of Applied Physiology
Volume66
Issue number6
StatePublished - 1989

Fingerprint

Magnesium Sulfate
Bronchoconstriction
Hypocapnia
Acetylcholine
Lung
Air
Nifedipine
Magnesium
Canidae
Bronchoscopes
Bronchodilator Agents
Calcium Channel Blockers
Intravenous Infusions
Serum

ASJC Scopus subject areas

  • Endocrinology
  • Physiology
  • Orthopedics and Sports Medicine
  • Physical Therapy, Sports Therapy and Rehabilitation

Cite this

Effect of magnesium sulfate on bronchoconstriction in the lung periphery. / Lindeman, Karen Sue; Hirshman, C. A.; Freed, A. N.

In: Journal of Applied Physiology, Vol. 66, No. 6, 1989, p. 2527-2532.

Research output: Contribution to journalArticle

Lindeman, Karen Sue ; Hirshman, C. A. ; Freed, A. N. / Effect of magnesium sulfate on bronchoconstriction in the lung periphery. In: Journal of Applied Physiology. 1989 ; Vol. 66, No. 6. pp. 2527-2532.
@article{d33218a7f14e433fbd0a78f3352b9994,
title = "Effect of magnesium sulfate on bronchoconstriction in the lung periphery",
abstract = "Magnesium sulfate has been shown to be effective clinically as a bronchodilator, but its mechanism of action is unknown. We used a wedged bronchoscope technique to study the ability of MgSO4 at clinically relevant concentrations to attenuate hypocapnia-, acetylcholine- (ACh), and dry air-induced bronchoconstriction in the canine lung periphery. Control experiments demonstrated that consecutive challenges of either hypocapnia or ACh resulted in greater collateral system resistance (Rcs) after the second challenge compared with the first. Intravenous infusion of MgSO4 diminished the maximum response to a second hypocapnic challenge (Rcs = 1.59 ± 0.29 cmH2O·ml-1·s prechallenge vs. 1.12 ± 0.20 postchallenge) but had no effect on either ACh- or dry air-induced bronchoconstriction. Serum magnesium levels before MgSO4 administration were 1.59 ± 0.04 meq/l and rose to 6.20 ± 0.13 during the infusion. Previous studies demonstrated that nifedipine, like MgSO4 in this study, attenuates hypocapnia-induced bronchoconstriction in the canine lung periphery but has no effect on ACh- or dry air-induced bronchoconstriction. We conclude that these results are consistent with the idea that, like nifedipine, magnesium acts in the airway as a voltage-sensitive calcium channel blocker.",
author = "Lindeman, {Karen Sue} and Hirshman, {C. A.} and Freed, {A. N.}",
year = "1989",
language = "English (US)",
volume = "66",
pages = "2527--2532",
journal = "Journal of Applied Physiology",
issn = "0161-7567",
publisher = "American Physiological Society",
number = "6",

}

TY - JOUR

T1 - Effect of magnesium sulfate on bronchoconstriction in the lung periphery

AU - Lindeman, Karen Sue

AU - Hirshman, C. A.

AU - Freed, A. N.

PY - 1989

Y1 - 1989

N2 - Magnesium sulfate has been shown to be effective clinically as a bronchodilator, but its mechanism of action is unknown. We used a wedged bronchoscope technique to study the ability of MgSO4 at clinically relevant concentrations to attenuate hypocapnia-, acetylcholine- (ACh), and dry air-induced bronchoconstriction in the canine lung periphery. Control experiments demonstrated that consecutive challenges of either hypocapnia or ACh resulted in greater collateral system resistance (Rcs) after the second challenge compared with the first. Intravenous infusion of MgSO4 diminished the maximum response to a second hypocapnic challenge (Rcs = 1.59 ± 0.29 cmH2O·ml-1·s prechallenge vs. 1.12 ± 0.20 postchallenge) but had no effect on either ACh- or dry air-induced bronchoconstriction. Serum magnesium levels before MgSO4 administration were 1.59 ± 0.04 meq/l and rose to 6.20 ± 0.13 during the infusion. Previous studies demonstrated that nifedipine, like MgSO4 in this study, attenuates hypocapnia-induced bronchoconstriction in the canine lung periphery but has no effect on ACh- or dry air-induced bronchoconstriction. We conclude that these results are consistent with the idea that, like nifedipine, magnesium acts in the airway as a voltage-sensitive calcium channel blocker.

AB - Magnesium sulfate has been shown to be effective clinically as a bronchodilator, but its mechanism of action is unknown. We used a wedged bronchoscope technique to study the ability of MgSO4 at clinically relevant concentrations to attenuate hypocapnia-, acetylcholine- (ACh), and dry air-induced bronchoconstriction in the canine lung periphery. Control experiments demonstrated that consecutive challenges of either hypocapnia or ACh resulted in greater collateral system resistance (Rcs) after the second challenge compared with the first. Intravenous infusion of MgSO4 diminished the maximum response to a second hypocapnic challenge (Rcs = 1.59 ± 0.29 cmH2O·ml-1·s prechallenge vs. 1.12 ± 0.20 postchallenge) but had no effect on either ACh- or dry air-induced bronchoconstriction. Serum magnesium levels before MgSO4 administration were 1.59 ± 0.04 meq/l and rose to 6.20 ± 0.13 during the infusion. Previous studies demonstrated that nifedipine, like MgSO4 in this study, attenuates hypocapnia-induced bronchoconstriction in the canine lung periphery but has no effect on ACh- or dry air-induced bronchoconstriction. We conclude that these results are consistent with the idea that, like nifedipine, magnesium acts in the airway as a voltage-sensitive calcium channel blocker.

UR - http://www.scopus.com/inward/record.url?scp=0024370926&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024370926&partnerID=8YFLogxK

M3 - Article

C2 - 2501286

AN - SCOPUS:0024370926

VL - 66

SP - 2527

EP - 2532

JO - Journal of Applied Physiology

JF - Journal of Applied Physiology

SN - 0161-7567

IS - 6

ER -